Status:
ACTIVE_NOT_RECRUITING
Accelerating Lung Cancer Diagnosis Through Liquid Biopsy
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Lung Health Foundation
The Princess Margaret Cancer Foundation
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will assess the utility of liquid biopsy to accelerate the time to treatment for patients with newly diagnosed advanced non-small cell lung cancer, compared to the conventional diagnostic p...
Eligibility Criteria
Inclusion
- Lung RAMP Multidisciplinary Cancer Conference or study team confirms radiologic (clinical) evidence of advanced, unresectable lung cancer;
- Measurable disease (presumed malignant) by RECIST 1.1;
- Age ≥18 years;
- Ability to provide written informed consent;
- Diagnostic biopsy and molecular profiling ordered or planned. Patients remain eligible even if biopsy or tumour testing later fails or is deemed not feasible.
Exclusion
- Pregnancy;
- Concurrent active malignancy except for localized non-melanomatous skin cancer or non-invasive cervical cancer. Any previous cancer (excluding NSCLC) must have been treated more than 2 years prior to study entry with no current evidence of active disease.
Key Trial Info
Start Date :
January 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT04863924
Start Date
January 14 2021
End Date
December 1 2026
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Canada